Laila Rowena Barbosa

Prof. Laila Rowena Barbosa

Universidade do Estado do Amazonas
+1
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
JBJose Diego Brito-Sousa
Jose Diego Brito-Sousa
FMFelipe Murta
Felipe Murta
SVSheila Vitor-Silva
Sheila Vitor-Silva
VSVANDERSON SOUZA SAMPAIO
VANDERSON SOUZA SAMPAIO
MMMaxwell Mendes
Maxwell Mendes
MLMarcus Vinícius Guimarães de Lacerda
Marcus Vinícius Guimarães de Lacerda
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency testing is not routinely performed before primaquine treatment in most Plasmodium vivax endemic areas, despite the risk of primaquine-associated hemolysis. This is due to the operational challenges associated with pragmatic G6PD testing and as such needs to be addressed. Methods and findings: This mixed-methods operational study was aimed at implementing the quantitative point-of-care StandardTM G6PD (SD Biosensor, Korea) screening test in malaria treatment units (MTUs) in the municipalities of Rio Preto da Eva and Mâncio Lima, in the Brazilian Amazon, between mid-January 2020 and December 2020. In total, 1286 P. vivax cases were treated based on the Standard G6PD test: 1230 had activity equal to or greater than 4.0 U/g Hb, and 56 less than 4.0 U/g Hb. No G6PD deficient (G6PDd) genotypes were found in 96 samples from the 1230, and only 21 of the 56 G6PDd cases had confirmed G6PDd genotypes. Evaluations were conducted on the proficiency of health care professionals (HCPs) training to perform the test, the reliability of testing performed in the field, and the perceptions of HCPs and patients about the implementation. Post-training proficiency was 73.4% after a 4-hour training session. This study revealed that locations with lower malaria caseloads will need regular refresher training. The test was well accepted by both HCPs and patients. Signs and symptoms of hemolysis were not always associated with malaria treatment drugs by HCPs and patients. Interpretation: Point-of-care quantitative G6PD testing can be performed at MTUs in the Brazilian Amazon to inform treatment decisions with primaquine. Limitations related to technical and cultural aspects need to be addressed further when expanding screening to larger areas.

18 May 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
JBJose Diego Brito-Sousa
Jose Diego Brito-Sousa
FMFelipe Murta
Felipe Murta
SVSheila Vitor-Silva
Sheila Vitor-Silva
VSVANDERSON SOUZA SAMPAIO
VANDERSON SOUZA SAMPAIO
MMMaxwell O. Mendes
Maxwell O. Mendes
MLMarcus Vinícius Guimarães de Lacerda
Marcus Vinícius Guimarães de Lacerda
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency greatly hinders Plasmodium vivax malaria radical cure and further elimination due to 8-aminoquinolines-associated hemolysis. Although the deleterious health effects of primaquine in G6PD deficient individuals have been known for over 50 years, G6PD testing is not routinely performed before primaquine treatment in most P. vivax endemic areas. Method/Principal findings: The qualitative CareStart G6PD screening test was implemented in 12 malaria treatment units (MTUs) in the municipality of Rio Preto da Eva, Western Brazilian Amazon, a malaria endemic area, between February 2019 and early January 2020. Training materials were developed and validated; evaluations were conducted on the effectiveness of training health care professionals (HCPs) to perform the test, the interpretation and reliability of routine testing performed by HCPs, and perceptions of HCPs and patients. Most HCPs were unaware of G6PD deficiency and primaquine-related adverse effects. Most of 110 HCPs trained (86/110, 78%) were able to correctly perform the G6PD test after a single 4-hour training session. The test performed by HCPs during implementation showed 100.0% (4/4) sensitivity and 68.1% (62/91) specificity in identifying G6PD deficient patients as compared to a point-of-care quantitative test (Standard G6PD). Conclusions/Significance: G6PD screening using the qualitative CareStart G6PD test performed by HCPs in MTUs of an endemic area showed high sensitivity and concerning low specificity. The amount of false G6PD deficiency detected led to substantial loss of opportunities for radical cure.

1 January 2020 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
Wuelton MonteiroWuelton Monteiro
Wuelton Monteiro
MBMaria das Graças Vale Barbosa
Maria das Graças Vale Barbosa
Jader de OliveiraJader de Oliveira
Jader de Oliveira
GMGisely Cardoso de Melo
Gisely Cardoso de Melo
Laila Rowena BarbosaLaila Rowena Barbosa
Laila Rowena Barbosa
MLMarcus Vinicius Guimarães de Lacerda
Marcus Vinicius Guimarães de Lacerda
Surveillance activities that are well developed in one area may act as driving forces for strengthening surveillance activities in other areas1. For instance, in the vast Amazon region in which malaria transmission mostly occurs, often in remote areas, there are pockets of biodiversity with varied triatomine vectors and mammalian Trypanosoma cruzi reservoirs, and thus, there is a risk of Chagas disease transmission2. This overlap offers possible synergies and opportunities for the use of common resources for the surveillance of both of the aforementioned protozoan febrile diseases.

13 March 2017 in Malaria Journal
Verified
Journal Article
Open access
PDF file
LBLarissa W. Brasil
Larissa W. Brasil
Laila Rowena BarbosaLaila Rowena Barbosa
Laila Rowena Barbosa
FAFelipe J. de Araujo
Felipe J. de Araujo
ACAllyson Guimarães Costa
Allyson Guimarães Costa
LSLuan D. O. da Silva
Luan D. O. da Silva
RRRajendranath Ramasawmy
Rajendranath Ramasawmy
Toll-interacting protein is a negative regulator in the TLR signaling cascade, particularly by impeding the TLR2 and, TLR4 pathway. Recently, TOLLIP was shown to regulate human TLR signaling pathways. Two common TOLLIP polymorphisms (rs5743899 and rs3750920) were reported to be influencing IL-6, TNF and IL-10 expression. In this study, TOLLIP variants were investigated to their relation to Plasmodium vivax malaria in the Brazilian Amazon. This cohort study was performed in the municipalities of Careiro and, Manaus, in Western Brazilian Amazon. A total of 319 patients with P. vivax malaria and, 263 healthy controls with no previous history of malaria were included in the study. Genomic DNA was extracted from blood collected on filter paper, using the QIAamp® DNA Mini Kit, according to the manufacturer’s suggested protocol. The rs5743899 and rs3750920 polymorphisms of the TOLLIP gene were typed by PCR–RFLP. Homozygous individuals for the rs3750920 T allele gene had twice the risk of developing malaria when compared to individuals homozygous for the C allele (OR 2.0 [95% CI 1.23–3.07]; p = 0.004). In the dominant model, carriers the C allele indicates protection to malaria, carriers of the C allele were compared to individuals with the T allele, and the difference is highly significant (OR 0.52 [95% CI 0.37–0.76]; p = 0.0006). The linkage disequilibrium between the two polymorphisms was weak (r2 = 0.037; D′ = 0.27). These findings suggest that genes involved in the TLRs-pathway may be involved in malaria susceptibility. The association of the TOLLIP rs3750920 T allele with susceptibility to malaria further provides evidence that genetic variations in immune response genes may predispose individuals to malaria.

30 June 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
MMMarielle M Macêdo
Marielle M Macêdo
AAAnne C. G. Almeida
Anne C. G. Almeida
GSGabrielly S. Silva
Gabrielly S. Silva
AOAmanda Carvalho Oliveira
Amanda Carvalho Oliveira
VMVictor Irungu Mwangi
Victor Irungu Mwangi
GMGISELY DE MELO
GISELY DE MELO
In the Amazon, the treatment for Plasmodium vivax is chloroquine plus primaquine. However, this regimen is limited due to the risk of acute hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency. Primaquine is a prodrug that requires conversion by the CYP2D6 enzyme to be effective against malaria. A series of cases were performed at an infectious diseases reference hospital in the Western Brazilian Amazon. The STANDARD G6PD (SD Biosensor®) assay was used to infer G6PD status and real-time PCR to genotype G6PD, CYP2C19, CYP2D6 and CYP3A4. Eighteen patients were included, of which 55.6% had African A− variant (G202A/A376G), 11.1% African A+ variant (A376G), 5.6% Mediterranean variant (C563T) and 27.8% were wild type. CYP2C19, CYP2D6 and CYP3A4 genotyping showed no statistically significant differences in the frequency of star alleles between the groups G6PD deficient and G6PD normal. Elevated levels of liver and kidney markers in the G6PDd patients were observed in gNM, gRM and gUM of CYP2C19 and CYP2D6 (p < 0.05). Furthermore, in this study there was no influence of CYPs on hemolysis. These findings reinforce the importance of studies on the mapping of G6PD deficiency and genetic variations of CYP2C19, CYP2D6 and CYP3A4. This mapping will allow us to validate the prevalence of CYPs and determine their influence on hemolysis in patients with malaria, helping to decide on the treatment regimen.

30 December 2020 in Pathogens
Verified
Journal Article
Open access
PDF file
Laila Rowena BarbosaLaila Rowena Barbosa
Laila Rowena Barbosa
ESEmanuelle L. da Silva
Emanuelle L. da Silva
AAAnne C. G. de Almeida
Anne C. G. de Almeida
YSYanka Salazar
Yanka Salazar
ASAndré M. Siqueira
André M. Siqueira
GMGisely Cardoso De Melo
Gisely Cardoso De Melo
Background: Early recurrence of Plasmodium vivax is a challenge for malaria control in the field, particularly because this species is associated with lower parasitemia, which hinders diagnosis and monitoring through blood smear testing. Early recurrences, defined as the persistence of parasites in the peripheral blood despite adequate drug dosages, may arise from resistance to chloroquine. The objective of the study was to estimate early recurrence of P. vivax in the Brazilian Amazon by using a highly-sensitive detection method, in this case, PCR. Methods: An ultra-sensitive qPCR that targeted mitochondrial DNA was used to compare a standard qPCR that targeted 18S rDNA to detect early recurrence of P. vivax in very low densities in samples from patients treated with chloroquine. Results: Out of a total of 312 cases, 29 samples (9.3%) were characterized as recurrences, from which 3.2% (10/312) were only detected through ultra-sensitive qPCR testing. Conclusions: Studies that report the detection of P. vivax early recurrences using light microscopy may severely underestimate their true incidence.